<div>
  <ul>
    <li>
      <p>
        Cell analysis technology company Cytomos raised GBP 5 million (USD 6.3 million) in an oversubscribed funding round led by Archangels, with participation from Old College Capital, Scottish Enterprise, and British Business Bank.
      </p>
    </li>
    <li>
      <p>
        The funding will scale up production and commercialize Celledonia, a product developed on the AuraCyt cell-analysis technology platform.
      </p>
    </li>
    <li>
      <p>
        Edinburgh-based life sciences company Cytomos has developed a proprietary cell analysis platform called Cytomos Dielectric Spectroscopy (CDS). CDS is a novel approach to analyzing cells, providing a low-cost, portable, and scalable alternative to traditional systems. The company's AuraCyt platform enables biopharma companies to bring novel therapies to market up to six months faster.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/latest-pharmaceutical-manufacturing-news/cytomos-secures-5m-to-scale-up-production-cell-analysis/">
      European Pharmaceutical Manufacturer
    </a>
  </p>
  <p>
    <a href="https://longevity.technology/news/cytomos-raises-5m-to-advance-scalable-cell-analysis-tech-for-drug-discovery/">
      Longevity Technology
    </a>
  </p>
</div>


Longevity Tech

<div>
 <p>Cytomos, a cell analysis technology firm, has raised GBP 5 million (USD 6.3 million) in a funding round that was oversubscribed. The round was led by Archangels and included participation from Old College Capital, Scottish Enterprise, and the British Business Bank.</p>
 <p>The funding will be used to escalate the production and commercialization of Celledonia, a product based on the AuraCyt cell-analysis technology platform.</p>
 <p>Based in Edinburgh, Cytomos has innovated a unique cell analysis platform named Cytomos Dielectric Spectroscopy (CDS). CDS offers an affordable, portable, and scalable alternative to traditional systems for analyzing cells. The company's AuraCyt platform allows biopharma firms to bring new therapies to the market, reducing the time to market by up to six months.</p>
</div>

Cytomos secures USD 6.3 million in oversubscribed funding to advance scalable cell-analysis

ANALYST_QUICK_TAKE

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 
 <p>ŌURA, a smart ring company, recently raised USD 75 million in a Series D funding round. The investment, provided by glucose monitoring device manufacturer Dexcom, values ŌURA at a staggering USD 5 billion. This latest round brings the total funding secured by ŌURA so far to USD 223.3 million.</p>
 <p>While ŌURA has not explicitly stated how it plans to utilize the recently raised funds, it has announced a strategic partnership with Dexcom. The partnership will focus on integrating their respective devices and apps, with the first app integration slated to be launched in the first half of 2025. Both firms will also engage in collaborative co-marketing and cross-selling strategies.</p>
 <p>ŌURA has already managed to sell 2.5 million rings and anticipates that it will be able to double its yearly sales figures to approximately USD 500 million come 2024. Furthermore, a reported 97% of ŌURA's user base is interested in understanding how food intake impacts their overall health.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> <a href="https:<br>
//sp-edge.com/updates/35536"> Last month </a> , ŌURA acquired Sparta Science, a Bay Area-based health-tracking startup that offers a data platform to analyze health and performance information, for an undisclosed sum. With this investment and partnership, the company appears to be growing rapidly. This might be an attempt to counter the threats from larger entrants to the smart ring market, such as Samsung.</p>

ŌURA raises USD 75 million in Series D funding from Dexcom; secures partnership to integrate into devices and apps

<div>
 <p>OneSkin, a skincare biotechnology firm has secured USD 20 million in a Series A funding. The round was led by Selva Ventures with participation from Unilever Ventures, and others. The fund will be used to accelerate the development of anti-aging skincare products and longevity solutions. Additionally, the investment aims to increase human capital for growth opportunities and develop new sales channels.</p>
 <p>OneSkin was founded in 2016 by a team of female scientists specializing in skin regeneration, aging, and bioinformatics. The company's patented peptide, OS-01, has been proven to reverse skin's biological age and improve overall skin health. OneSkin aims to create skincare products that promote skin longevity and health at a molecular level.</p>
</div>

OneSkin raises USD 20 million in Series A funding to accelerate skin longevity research

<div>
 <p>The Longevity Investors Conference (LIC) 2024 was recently held in Gstaad, Switzerland, hosting 130 participants comprising of scientists, investors, and technology experts. The attendees gathered to discuss human longevity advancements.</p>
 
<p>Renowned speakers such as Dr. David Sinclair of Harvard Medical School, Dr. Nir Barzilai from Albert Einstein College of Medicine, and Dr. Aubrey de Grey from the LEV Foundation were present. The discussions circled around four main areas: Longevity investment, general longevity, personal longevity, and longevity science.</p>
 
<p>A Startup Showcase featuring 10 companies including Micregen, Leucadia Therapeutic, and Kyttaro Therapeutics was also part of the conference. These companies presented their solutions in regenerative medicine and disease prevention. LIC further announced its expansion plans into Asia in Q2 2025, with plans to host the Longevity Investors Lunch during the World Economic Forum in Davos, Switzerland, on January 21, 2025. Registrations for LIC 2025 will be opening thereafter.</p>
</div>

Longevity Investors Conference 2024 gathers leaders in Switzerland

<div>

 <p>Ōura, a company known for their smart ring, has recently acquired the Bay Area-based health tracking startup, Sparta Science. The terms of the deal have not been disclosed. Sparta Science's hallmark product is the Trinsic platform, a data-centric platform that helps enterprise clients track health vitals and analyze health and performance metrics.</p>
 <p>With this latest acquisition, Ōura plans to merge Trinsic into its business-to-business (B2B) service, Ōura Teams. The integration will enable enterprise partners to combine and analyze data from the Ōura ring with other third-party sources. This consolidation will provide valuable insights into fitness and safety measures. Additionally, it will also allow for the creation of customized dashboards, specifically tailored for healthcare and government clients.</p>
  
</div> <p><b>Analyst Quicktake:<br>
 </b> This marks the second acquisition Ōura has carried out in 2024. In <a href="https:<br>
//sp-edge.com/updates/33488"> September </a> , the company acquired Veri, a Finnish personalized metabolic health company, for an undisclosed amount. The company noted that the acquisition of Veri was carried out to integrate Veri's expertise, expanding Ōura’s offerings in metabolic health. With its acquisition of Sparta Science, Ōura is further expanding its offerings to maintain its market position against competitors such as Samsung and Happy Health.</p>

Ōura acquires health tracking startup Sparta Science for undisclosed sum

<div>

<p>Ōura Health, a Finnish company specializing in wearable technology, has unveiled its latest smart ring, the Ring 4. Selling for USD 349, this new model replaces the previous Ring 3, offering enhanced health tracking capabilities.</p>
<p>Compared to its previous version, the Ring 4 comprises twice the amount of sensors, utilizes algorithms crafted for each user's unique physiological features, and is crafted from sleek titanium with embedded sensors. Blood oxygen and heart rates, especially during sleep, can be monitored with improved accuracy.</p>
<p>An independent study has found that the Ring 4's blood oxygen data has improved by 30% in terms of accuracy, heart rate measurements have fewer gaps, and the index tracking breathing disturbances is 15% more accurate. In addition, the new model offers an extended battery life, lasting up to eight days on one charge.</p>

</div> <p><b>Analyst QuickTake:<br>
 </b> In <a href="https:<br>
//sp-edge.com/updates/33488"> September 2024 </a> , Ōura Health acquired metabolic health company Veri for an undisclosed sum. Through the acquisition, it planned to incorporate Veri's expertise to expand its offerings in metabolic health.</p>

Ōura launches Ring 4 with improved health tracking accuracy

<div>
 
 <p>Integrated Biosciences, a biotechnology firm, has successfully amassed USD 17M in a seed funding endeavor. Leading this effort was Sutter Hill Ventures, with notable contributions also coming from Root Ventures, Civilization Ventures, Illumina Ventures Labs, Lifespan Vision Ventures, Overlap Holdings, SH Fund (Sabrina Hahn), Conscience VC, Mission BioCapital, Reinforced Ventures, Polymath Capital, Michael Stoppelman, and Vijay Pandurangan.</p>
 
 <p>The capital raised is expected to significantly benefit Integrated Biosciences' developmental pursuits. Its primary plans for the funds involve the advancement of its drug range and platform and bolstering its commercialization strides. </p>
 
 <p>The company specializes in the invention of innovative methods that fuse synthetic biology with AI-empowered small-molecule drug discovery. This synergy aspires to create treatments that cater to age-associated maladies.</p>
 
</div>

Integrated Biosciences raises USD 17 million in seed funding for further development of pipeline and platform

<div>
 
 <p>BioAge Labs has declared the price of its increased initial public offering at a total of USD 198 million. This includes 11 million of common stocks at USD 18 per share. The company has also offered underwriters a chance to buy an extra 1.65 million shares within 30 days of the initial offering, less the underwriter discounts and commissions.</p>
 <p>This offering is forecasted to conclude by September 27, 2024, and the shares are expected to start being traded on the Nasdaq Global Select Market a day earlier, on September 26, 2024, using the ticker symbol “BIOA.”</p>
 
</div>

BioAge Labs prices upsized initial public offering

<div>

 <p>Amprion has received a USD 100,000 grant from The ALS Network. The company will use these funds to conduct research to understand the cause of sporadic amyotrophic lateral sclerosis (ALS) and to develop potential therapies. This includes supporting necessary clinical and lab research, as well as the development of lab tests to detect other misfolding proteins connected to ALS pathology.</p>
 <p>The company specializes in diagnostic tests for neurodegenerative diseases, identifying misfolded proteins correlated with illnesses such as Parkinson’s disease, Lewy body dementia (LBD), and Alzheimer’s disease with Lewy bodies. Amprion's flagship product, the SAAmplify-ɑSYN Test, uses a seed amplification assay (SAA) method to recognize misfolded proteins before the disease symptoms become apparent. </p>

</div>

Amprion raises USD 100,000 in research grant funding from ALS Network to support ALS research and therapy development

<div>
 
 <p>Ōura, a health wearable device company, has acquired Veri, a Finnish metabolic health firm. A substantial part of Veri's team, including its three founders, will join Ōura. Veri provides users with personalized food recommendations and healthy habits through a glucose monitor-enabled app. This helps individuals understand their nutritional impact, facilitate weight loss, enhance energy, and improve sleep.</p>
 <p>Ōura is set to use Veri's expertise to extend its metabolic health services, an area of significant interest for its members. The company plans to launch a new Meals feature this fall, allowing members to monitor meal times and comprehend the effect of their eating habits on health aspects like sleep, stress, and recovery.</p>
 
</div> <p><b>Analyst QuickTake</b> :<br>
 Traditionally, Ōura has tried to maintain its market share by <a href="https:<br>
//sp-edge.com/updates/30034"> suing potential new entrants </a> . However, this strategy fell apart when Samsung countered Ōura’s strategy by <a href="https:<br>
//sp-edge.com/updates/30034"> preemptively suing </a> the company before launching its Galaxy Ring. Now, it appears that Ōura is attempting to maintain its market presence by expanding its product features, as it plans to integrate Veri’s CGM functions into its wearable. The latest version of the ring, which could incorporate these features, is <a href="https:<br>
//techcrunch.com/2024/09/11/oura-has-acquired-metabolic-heath-startup-veri/"> rumored to be released soon </a> .</p>

All Updates

Cytomos secures USD 6.3 million in oversubscribed funding to advance scalable cell-analysis

ŌURA raises USD 75 million in Series D funding from Dexcom; secures partnership to integrate into devices and apps

OneSkin raises USD 20 million in Series A funding to accelerate skin longevity research

Longevity Investors Conference 2024 gathers leaders in Switzerland

Ōura acquires health tracking startup Sparta Science for undisclosed sum

Ōura launches Ring 4 with improved health tracking accuracy

Integrated Biosciences raises USD 17 million in seed funding for further development of pipeline and platform

BioAge Labs prices upsized initial public offering

Amprion raises USD 100,000 in research grant funding from ALS Network to support ALS research and therapy development

Ōura acquires metabolic health company Veri for undisclosed sum

Longevity Tech

Cytomos secures USD 6.3 million in oversubscribed funding to advance scalable cell-analysis

Contact us